Why the study?
Do circulating biomarkers (MR-proADM, sTNFR1, and NT-proBNP) improve risk prediction for renal function decline in patients with type 2 diabetes?
Population
1,135 patients with type 2 diabetes in a French prospective cohort
Design
Cohort
Key result
Circulating biomarkers MR-proADM, sTNFR1, and NT-proBNP independently predicted renal function loss in type 2 diabetes, with MR-proADM yielding an adjusted HR of 1.59 (95% CI 1.34-1.89; P<0.0001).
Authors
Loading...
May enhance renal risk stratification in type 2 diabetes; leaves open prospective validation before clinical adoption.
Cohort (n=1,135)
Do circulating biomarkers (MR-proADM, sTNFR1, and NT-proBNP) improve risk prediction for renal function decline in patients with type 2 diabetes?
Hazard Ratio: 1.59 (95% CI 1.34–1.89)
p-value: p=<0.0001
The addition of MR-proADM, sTNFR1, and NT-proBNP to established risk factors significantly improves the prediction of renal function decline in patients with type 2 diabetes.
Saulnier et al. (2016) conducted a cohort in Type 2 Diabetes (n=1,135). Circulating biomarkers (MR-proADM, sTNFR1, and NT-proBNP) was evaluated on Renal function loss (≥40% decline of eGFR from baseline) (HR 1.59, 95% CI 1.34-1.89, p=<0.0001). Circulating biomarkers MR-proADM, sTNFR1, and NT-proBNP independently predicted renal function loss in type 2 diabetes, with MR-proADM yielding an adjusted HR of 1.59 (95% CI 1.34-1.89; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: